Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Abbott, J&J Reaffirm 2025 Profit Guidance Despite Growing Tariff Uncertainties

Apr 17 2025

• By Marion Webb

(Shutterstock)

Related Content

China’s Biotech Stocks Proved More Resilient Than US’s Amid Market Turmoil

Apr 17 2025

Trump Executive Order On Drug Pricing Is A Mixed Bag For Pharma

Apr 16 2025

Keeping Germany’s Medtech Industry Apprised, Advised and Incentivized in Turbulent Times

Apr 16 2025

Indian Medtechs Call US Tariffs A Challenge To Growth And Seek Reciprocal Regulatory Access

Apr 16 2025

Biotech Leaders Ponder Trump’s Tariff Ramifications

Apr 21 2025

Medtech Looks For Relief As Trump Hits Pause On Most Tariffs

Apr 09 2025

Shuren Expects Longer CDRH Review Times

Apr 08 2025

US Pharma Tariff Reprieve Appears Short-Lived

Apr 07 2025

UK Treading A Tightrope On Trump’s Tariffs

Apr 04 2025

US Medtech Tariffs: How Will EU Navigate Unchartered Territory?

Apr 04 2025

Medtech Industry Faces Tariffs Despite Pleas for Exemption

Apr 03 2025

Swiss Blast US Import Tariffs As Medtechs Look For Dialog To Forestall Damage To Industry

Apr 03 2025

Additional Topics

Leadership Tariffs Regulation Financing

More from Regulation

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window